Belite Bio, Inc (BLTE)
| Market Cap | 343.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.67M |
| Shares Out | 24.10M |
| EPS (ttm) | -0.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,507 |
| Open | 14.20 |
| Previous Close | 14.08 |
| Day's Range | 14.20 - 14.62 |
| 52-Week Range | 8.80 - 17.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BLTE
Belite Bio is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration (commonly known as dry AMD) and autosomal recessive Stargardt disease, or STGD1, both of which progressively lead to permanent blindness, and, at the preclinical development stage, metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. Our lead product can...
Financial Performance
Financial StatementsNews
Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye di...
Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022
SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (the “Company”) (Nasdaq: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable e...